Evidence map›Paper›PMID 38887478›Full record

ArticleOpen forum infectious diseases2024

Combination Antifungal Therapy for Invasive Mucormycosis in Immunocompromised Hosts: A Single-Center Experience.

Brian Lu, David Ha, Sa Shen, Jessica Ferguson Toll, Ailin Kim, Sarah Kim, Emily Mui, Stan Deresinski, Marisa Holubar, William Alegria

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review of the Microbial Spectrum of Mixed Respiratory Fungal Infections.Journal of epidemiology and global health · 2026
    Review
  3. Article
  4. Mucormycosis.Infectious disease clinics of North America · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Brian LuDepartment of Pharmacy, Stanford Health Care, Stanford, California, USA.ORCID https://orcid.org/0000-0002-6381-5499
David HaDepartment of Quality, Stanford Health Care, Stanford, California, USA.
Sa ShenQuantitative Sciences Unit, School of Medicine, Stanford University, Stanford, California, USA.
Jessica Ferguson TollDivision of Infectious Diseases and Geographic Medicine, School of Medicine, Stanford University, Stanford, California, USA.
Ailin KimDepartment of Pharmacy, Stanford Health Care, Stanford, California, USA.
Sarah KimDepartment of Pharmacy, Stanford Health Care, Stanford, California, USA.
Emily MuiDepartment of Quality, Stanford Health Care, Stanford, California, USA.
Stan DeresinskiDepartment of Quality, Stanford Health Care, Stanford, California, USA.
Marisa HolubarDepartment of Quality, Stanford Health Care, Stanford, California, USA.ORCID https://orcid.org/0000-0002-7585-1809
William AlegriaDepartment of Quality, Stanford Health Care, Stanford, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combination antifungal therapy for invasive mucormycosis remains controversial and is inconsistently defined in prior studies. In a cohort of patients with immunocompromised status and invasive mucormycosis, we found no difference in 6-week mortality with up-front or salvage combination therapy as compared with monotherapy.

Identifiers

PMID38887478
PMCPMC11181191

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.